Adipokine FABP4 integrates energy stores and counterregulatory metabolic responses
| Autor: | Kacey J. Prentice, Jani Saksi, Gökhan S. Hotamisligil |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
obesity immunometabolism Adipokine Adipose tissue QD415-436 030204 cardiovascular system & hematology Fatty Acid-Binding Proteins Bioinformatics Biochemistry Mice 03 medical and health sciences 0302 clinical medicine Endocrinology Diabetes mellitus medicine Animals Humans Glucose homeostasis adipocyte protein 2 biology Binding protein Cell Biology JLR Perspectives medicine.disease 3. Good health 030104 developmental biology biology.protein Energy Metabolism metabolism Intracellular Hormone |
| Zdroj: | Journal of Lipid Research, Vol 60, Iss 4, Pp 734-740 (2019) Journal of Lipid Research |
| ISSN: | 0022-2275 |
| Popis: | Although counterregulatory hormones and mediators of the fight-or-flight responses are well defined at many levels, how energy stores per se are integrated into this system remains an enigmatic question. Recent years have seen the adipose tissue become a central focus for mediating intracellular signaling and communication through the release of a variety of bioactive lipids and substrates, as well as various adipokines. A critical integration node among these mediators and responses is controlled by FA binding protein 4 (FABP4), also known as adipocyte protein 2 (aP2), which is highly expressed in adipose tissue and functions as a lipid chaperone protein. Recently, it was demonstrated that FABP4 is a secreted hormone that has roles in maintaining glucose homeostasis, representing a key juncture facilitating communication between energy-storage systems and distant organs to respond to life-threatening situations. However, chronic engagement of FABP4 under conditions of immunometabolic stress, such as obesity, exacerbates a number of immunometabolic diseases, including diabetes, asthma, cancer, and atherosclerosis. In both preclinical mouse models and humans, levels of circulating FABP4 have been correlated with metabolic disease incidence, and reducing FABP4 levels or activity is associated with improved metabolic health. In this review, we will discuss the intriguing emerging biology of this protein, including potential therapeutic options for targeting circulating FABP4. Graphical Abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|